FDA's Oncologic Drugs Advisory Committee Recommends Earlier Treatment with Carvykti for Relapsed or Refractory Multiple Myeloma; In a unanimous decision, the committee recommended Carvykti based on promising data from the Phase III CARTITUDE-4 study, whic

Media coverage

• Title	FDA's Oncologic Drugs Advisory Committee Recommends Earlier Treatment with Carvykti for Relapsed or Refractory Multiple Myeloma; In a unanimous decision, the committee recommended Carvykti based on promising data from the Phase III CARTITUDE-4 study, whic
  Media name/outlet	Pharmaceutical Executive
  Country/Territory	United States
  Date	1/03/24
  Persons	Sundar Jagannath